Loading...
XJPX
7777
Market cap324mUSD
Oct 09, Last price  
407.00JPY
1D
1.75%
1Q
15.95%
Jan 2017
-36.80%
IPO
9.93%
Name

3-D Matrix Ltd

Chart & performance

D1W1MN
XJPX:7777 chart
P/E
12.53
P/S
4.78
EPS
32.47
Div yield, %
—
Shrs. gr., 5y
27.09%
Rev. gr., 5y
60.43%
Revenues
10.89b
+57.00%
158,320,0001,107,387,00032,013,000107,160,00099,776,000141,834,000615,852,000228,615,000328,847,000672,418,0001,024,375,0001,506,230,0002,314,083,0004,588,818,0006,934,144,00010,886,312,000
Net income
4.16b
P
-533,952,000308,610,000-978,331,000-1,525,374,000-1,994,965,000-2,459,327,000-1,392,571,000-1,866,217,000-2,554,559,000-3,096,159,000-2,012,615,000-1,894,757,000-2,445,978,000-255,505,000-2,501,245,0004,155,850,999
CFO
397m
P
-433,762,000-131,013,000-655,715,000-1,679,990,000-1,904,814,000-1,463,852,000-1,887,017,000-2,020,656,000-2,301,529,000-2,189,247,000-3,249,736,000-2,903,268,000-4,585,082,000-1,899,876,000-1,714,099,000396,845,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

3-D Matrix, Ltd. specializes in advancing self-assembling peptide technology. The company's primary offering is PuraMatrix, an innovative self-assembling peptide hydrogel utilized across diverse medical sectors such as regenerative medicine, cell-based therapies, sophisticated drug delivery mechanisms, and various surgical applications. This Tokyo, Japan-based entity was founded in 2004.

Key people

Jun Okada
President, Representative Director · since 2016
Marie Buffer
Executive Officer · since 2021
Andy Kim
Executive Officer
Satoru Kobayashi
Executive Officer, Director of Business Development, Director · since 2021
Toshi Amanuma
Executive Officer, Senior Director of North American Business, Director · since 2021
Keiji Nagano
Chairman of the Board · since 2016
Kazuya Shimamura
Independent Director · since 2012
URL
https://www.3d-matrix.co.jp/
IPO date
Oct 24, 2011
Employees
108
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑042025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT